Cello Health acquires promedica

Cello Health has announced a further expansion with the acquisition of San Francisco-based market research company Worldwide Promedica Inc (‘Promedica’) - its second acquisition since launching earlier this year.

Promedica, founded in 1984, provides quantitative and qualitative primary market research in the healthcare sector, with a focus on biotechnology and rare or orphan disease.  Its clients include venture capital firms supporting biopharma start-ups and early product development.

The acquisition is the second this year by Cello Health, which bought iS Healthcare Dynamics in May.

Promedica will work closely with Cello Health’s market research arm Cello Health Insight, which is based in London, New York and Chicago, as well as Cello Health’s US capabilities in Consulting and Communications.  The move will open up Cello Health’s first capacity on the west coast of the US.

“This acquisition, and the introduction of Promedica’s experienced and talented team into Cello Health, will enable us to open up capacity on the west coast, where we are seeing significant activity and potential with both pharmaceutical and biotechnology clients,” commented Cello Health Chairman Stephen Highley.

“We are now very much focused on our expansion in the US through our three core capabilities in Insight, Consulting and Communications, and the acquisition of Promedica fits perfectly with this strategy.  Insight has grown tremendously from its London base, now with well-established offices in New York and Chicago, and this move is a logical next step, adding a presence on the west coast.

“We remain committed to growing our Consulting and Communications capabilities in the US, and have driven that both through acquisition (such as MedErgy HealthGroup) and through dynamic growth plans.”